Poll Results

With the approval of more biosimilars, how likely is the FDA to create an authorized generic pathway for BLAs?

Highly likely: 28.6%

Somewhat likely: 42.8%

Somewhat unlikely: 14.3%

Highly unlikely: 14.3%

If the proposed drug importation regulations are passed, what percent of the drug costs will be saved through products purchased under this regulation?

0%: 10%

1-10%: 90%

11-25%: 0%

>25%: 0%

How likely are payers to focus on formulary placement or exclusion for unapproved products (i.e. medical foods)?

Somewhat likely for exclusion purposes only: 72%

No change in focus from today: 14%

Unlikely: 14%

Highly likely: 0%

Biosimilars have gotten off to a slow start in the marketplace. What change will most dramatically affect the adoption rate?

PBM Formulary and coverage decisions: 83%

New Legislation: 17%

HHS/CMS Policy Changes: 0%

Who will be the slowest to adopt the electronic real-time benefit check?

Physicians: 53.8%

PBMs: 30.8%

EMRs: 15.4%

Surescripts: 0%

If the NADAC survey of pharmacy costs becomes mandatory, how will this impact the NADAC and Medicaid pharmacy reimbursement?

NADAC would decrease, resulting in lower Medicaid reimbursements to pharmacies:  88%

NADAC would not change and Medicaid reimbursements would remain the same:  12%

NADAC would increase, resulting in higher Medicaid reimbursements to pharmacies:  0%

What percent of new drugs in the next 5 years will use alternative payment models like subscription plans or multi-year payment plans?

0%:   0%

1% to 5%:   82%

5% to 10%:   9%

10% to 20%:   9%

20% to 30%:   0%

How quickly will payer and EHR real time benefit checks be implemented?

6 months:  0%

1 year:  0%

2 years:  75.0%

3 years:  12.5%

4 years or more:  12.5%

Never:  0%

HHS has proposed altering the safe harbor for pharmaceutical rebates. When will the proposed POS rebates be implemented for Medicare Part D and Medicaid plans?

2020:  27.27%

2021:  9.09%

2022:  9.09%

2023:  18.18%

Never:  36.36%